Suppr超能文献

华法林与精神类药物的药物相互作用:文献更新综述。

Drug-drug interactions between warfarin and psychotropics: updated review of the literature.

机构信息

Boston University Medical Center, Boston, Massachusetts 02118, USA.

出版信息

Pharmacotherapy. 2012 Oct;32(10):932-42. doi: 10.1002/j.1875-9114.2012.01119.

Abstract

As the number of psychotropics on the market expands, the likelihood increases that a patient requiring anticoagulation with warfarin will receive concurrent treatment with a psychotropic drug. Because warfarin undergoes hepatic metabolism and is highly protein bound, it is particularly prone to drug interactions; in addition, its relatively narrow therapeutic window places patients at risk of either hemorrhagic or thrombotic complications. Although warfarin's interactions with other drugs have long been studied, the most recent review of the literature of warfarin's interactions with psychotropics was over a decade ago. Thus, we conducted a systematic review of the literature documenting the interaction between warfarin and psychotropics, with a focus on interactions mediated through the cytochrome P450 system and protein binding. A search of the MEDLINE database was performed, and reports of warfarin interactions with psychotropics were identified. The results suggest that interactions between warfarin and psychotropic drugs are important and likely underrecognized. They also have notable implications for both safety and drug compliance. When certain psychotropics are started or discontinued in patients receiving warfarin therapy, or when warfarin is introduced to a patient receiving a stable dose of a psychotropic, clinicians should monitor a patient's international normalized ratio (INR) closely to ensure it remains within therapeutic range. Psychotropics that pose a particular risk of increasing the INR when used with warfarin include fluoxetine, fluvoxamine, quetiapine, and valproic acid. Psychotropics that may significantly decrease the INR when used with warfarin include trazodone, St. John's wort, carbamazepine, and the polycyclic aromatic carbons in tobacco cigarettes; however, nicotine itself, as in nicotine replacement strategies, is not known to alter warfarin's anticoagulant effect. In certain cases, the need for anticoagulation may also necessitate switching to a different psychotropic.

摘要

随着市场上精神类药物的种类不断增加,正在接受华法林抗凝治疗的患者同时使用精神类药物的可能性也会增加。由于华法林在肝脏中代谢,且与蛋白高度结合,因此特别容易发生药物相互作用;此外,其治疗窗相对较窄,患者易发生出血或血栓并发症。尽管华法林与其他药物的相互作用早已被广泛研究,但最近一次对华法林与精神类药物相互作用的文献综述也是在十多年前。因此,我们系统地回顾了文献,记录了华法林与精神类药物相互作用的情况,重点关注了通过细胞色素 P450 系统和蛋白结合介导的相互作用。我们对 MEDLINE 数据库进行了检索,并确定了华法林与精神类药物相互作用的报告。结果表明,华法林与精神类药物之间的相互作用很重要,但可能被低估了。这些相互作用对安全性和药物依从性都有显著影响。当正在接受华法林治疗的患者开始或停止使用某些精神类药物,或当正在接受稳定剂量精神类药物治疗的患者开始使用华法林时,临床医生应密切监测患者的国际标准化比值(INR),以确保其保持在治疗范围内。与华法林同时使用时,可能会显著增加 INR 的精神类药物包括氟西汀、氟伏沙明、喹硫平和丙戊酸。与华法林同时使用时,可能会显著降低 INR 的精神类药物包括曲唑酮、贯叶连翘、卡马西平和烟草香烟中的多环芳烃;然而,尼古丁本身(如尼古丁替代疗法)并不被认为会改变华法林的抗凝作用。在某些情况下,为了进行抗凝治疗,可能还需要更换其他精神类药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验